MY192577A - Ophthalmic solution comprising epinastine - Google Patents

Ophthalmic solution comprising epinastine

Info

Publication number
MY192577A
MY192577A MYPI2019002321A MYPI2019002321A MY192577A MY 192577 A MY192577 A MY 192577A MY PI2019002321 A MYPI2019002321 A MY PI2019002321A MY PI2019002321 A MYPI2019002321 A MY PI2019002321A MY 192577 A MY192577 A MY 192577A
Authority
MY
Malaysia
Prior art keywords
ophthalmic solution
epinastine
ingredients
salt
substantially free
Prior art date
Application number
MYPI2019002321A
Inventor
Masahiro Kawahata
Naoki Matsumoto
Hiroyuki Inoue
Tomoki Hara
Sachie Hikage
Takashi Morimoto
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY192577A publication Critical patent/MY192577A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provision of an ophthalmic solution comprising epinastine or a salt thereof which is substantially free of reservatives and ingredients with preservative efficacy. An ophthalmic solution comprising epinastine or a salt thereof in a concentration of over 0.075% (w/v) wherein the ophthalmic solution is substantially free of preservatives and ingredients with preservative efficacy.
MYPI2019002321A 2016-10-28 2017-10-27 Ophthalmic solution comprising epinastine MY192577A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016211535A JP6134853B1 (en) 2016-10-28 2016-10-28 Epinastine-containing ophthalmic solution
PCT/JP2017/038948 WO2018079721A1 (en) 2016-10-28 2017-10-27 Epinastin-containing eye drops

Publications (1)

Publication Number Publication Date
MY192577A true MY192577A (en) 2022-08-29

Family

ID=58745757

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019002321A MY192577A (en) 2016-10-28 2017-10-27 Ophthalmic solution comprising epinastine

Country Status (7)

Country Link
JP (1) JP6134853B1 (en)
KR (4) KR102659499B1 (en)
AU (1) AU2017348597A1 (en)
MY (1) MY192577A (en)
PH (1) PH12019500934A1 (en)
TW (1) TWI750248B (en)
WO (1) WO2018079721A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102766744B1 (en) * 2017-05-01 2025-02-11 산텐 세이야꾸 가부시키가이샤 Eye drop
JP7355539B2 (en) * 2018-07-20 2023-10-03 ロート製薬株式会社 Ophthalmic composition
JP7458159B2 (en) * 2018-09-28 2024-03-29 ロート製薬株式会社 Ophthalmic Composition
JP2019108320A (en) * 2018-10-31 2019-07-04 参天製薬株式会社 Ophthalmologic composition which suppresses deterioration of soft contact lens
JP6736752B2 (en) * 2019-12-17 2020-08-05 参天製薬株式会社 Eye drops containing epinastine
JP2020169213A (en) * 2020-07-15 2020-10-15 参天製薬株式会社 Epinastine-containing eye drops
WO2022138826A1 (en) * 2020-12-24 2022-06-30 参天製薬株式会社 Pharmaceutical composition for topical administration containing epinastine or salt thereof
KR20250126761A (en) * 2022-12-23 2025-08-25 산텐 세이야꾸 가부시키가이샤 Aqueous composition containing epinastine for improving tissue transportability and antiseptic effect

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19954516A1 (en) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Solutions containing epinastine
KR20110104367A (en) * 2010-03-16 2011-09-22 삼천당제약주식회사 Preservative-free ophthalmic composition
EP2664329A1 (en) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmological vehicle system
JPWO2015125921A1 (en) * 2014-02-20 2017-03-30 わかもと製薬株式会社 Pharmaceutical aqueous composition having storage efficacy

Also Published As

Publication number Publication date
KR20240054409A (en) 2024-04-25
KR102876762B1 (en) 2025-10-27
WO2018079721A1 (en) 2018-05-03
KR102659499B1 (en) 2024-04-19
JP6134853B1 (en) 2017-05-24
KR20230014870A (en) 2023-01-30
KR20190075956A (en) 2019-07-01
AU2017348597A1 (en) 2019-05-16
JP2018070500A (en) 2018-05-10
KR20250154566A (en) 2025-10-28
TWI750248B (en) 2021-12-21
TW201821060A (en) 2018-06-16
KR102491425B1 (en) 2023-01-20
PH12019500934A1 (en) 2019-12-02

Similar Documents

Publication Publication Date Title
MY192577A (en) Ophthalmic solution comprising epinastine
MX2019003364A (en) Ophthalmic compositions comprising ciclosporin.
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
SG10201811454WA (en) Materials and methods for controlling infections
MY182507A (en) Aqueous ophthalmic solution
WO2018211454A3 (en) Cryoprotectant and/or cryopreservant composition, methods and uses thereof
MY192532A (en) Liquid pharmaceutical composition
MY187945A (en) Improved mouthwash preparation
MX2018002546A (en) COMPOSITIONS THAT INCLUDE A UROLITINE COMPOUND.
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
MX385447B (en) ANTIHYPERTENSIVE AGENT
MX2018012285A (en) TREATMENT METHODS FOR COLESTIC AND FIBROTIC DISEASES.
MX379359B (en) DERIVATIVES OF 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECane.
MX2021015544A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
NZ733329A (en) Microbiocidal control in the processing of poultry
AR101581A1 (en) COLUTORY COMPOSITION
MY183391A (en) Refrigerant pack
PL3398436T3 (en) Storage-stable microbicidal concentrates and use thereof as preservatives
WO2015108999A8 (en) Bioactive heme-haloperoxidase compositions and methods of their use
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
GB2553870B (en) Sweat-inhibiting and/or deodorizing cosmetic agents with low emulsifier content
MX2019003764A (en) Aqueous composition derived from seawater and seaweed.
PH12016501448A1 (en) Antifungal composition
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease